A Phase 1/2 Dose Escalation Trial With Administration Schedule Exploration Evaluating Single Agent TD001, a PSMA-Targeted Antibody-Drug Conjugate, in Patients With PSMA-Expressing Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 07 Jan 2026
At a glance
- Drugs TD 001 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors T.O.A.D. Oncology SA
Most Recent Events
- 05 Dec 2025 New trial record